|  |
| --- |
| April 29, 2013 |
|  |
| Contact personsJanna HullmannCommunications BU Consumer SpecialtiesPhone +49 201 172-1410Fax +49 201 173-1838janna.hullmann@evonik.com  |
| Lisa DierksGlobal Marketing Communications Manager / Personal Care Phone +49 201 173-3170 Fax +49 201 173-713170lisa.dierks@evonik.com |
| Evonik Industries AGRellinghauser Straße 1-1145128 EssenGermanyPhone +49 201 177-01Fax +49 201 177-3475www.evonik.de**Supervisory Board**Dr. Werner Müller, ChairmanExecutive BoardDr. Klaus Engel, ChairmanDr. Wolfgang Colberg,Dr. Thomas Haeberle, Thomas Wessel, Patrik Wohlhauser, Dr. Dahai YuRegistered office EssenRegistered courtEssen local courtCommercial registry B 19474VAT ID no. DE 811160003 |

**TEGO® Stemlastin has been awarded as one of the innovative products in the category naturals/actives at in-cosmetics 2013**

BSB Innovation Award for cosmetics and raw materials reveals latest cosmetic inventions

The BSB Innovation Award highlights the best finished goods and ingredients in four different categories. Each prize winner is selected by an international and independent jury that consists of industry professionals from leading players.

Evonik`s TEGO® Stemlastin has been awarded in the category innovative raw material cosmetics naturals/actives.

TEGO® Stemlastin is a standarized red algae extract which is unique in its capability to produce GABA. It is produced in a natural, eco-friendly way using a photo bio-reactor. TEGO® Stemlastin shows proven combined activity on epidermal stem cells and elastic fibers.

**Please find appropriate image data and further information on our Personal Care website: www.evonik.com/personal-care**

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.